Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,240.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective boosted by Royal Bank of Canada from $1,232.00 to $1,240.00 in a report released on Friday morning, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

Several other analysts have also commented on the stock. Truist Financial reissued a buy rating and set a $1,200.00 price target (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday. UBS Group upped their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a buy rating in a report on Wednesday, April 17th. Bank of America upped their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an underperform rating in a report on Friday, April 12th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a report on Tuesday, April 30th. Finally, Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the company a neutral rating in a report on Monday, July 22nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $1,097.05.

Regeneron Pharmaceuticals Stock Down 1.0 %

Shares of REGN opened at $1,071.28 on Friday. Regeneron Pharmaceuticals has a 12-month low of $765.28 and a 12-month high of $1,115.00. The firm has a fifty day moving average price of $1,043.43 and a 200-day moving average price of $983.16. The firm has a market capitalization of $118.04 billion, a P/E ratio of 31.65, a P/E/G ratio of 2.34 and a beta of 0.13. The company has a current ratio of 5.96, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $8.79 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals will post 37.38 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 65,074 shares of company stock worth $64,546,123. Company insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock valued at $8,595,268,000 after purchasing an additional 91,956 shares in the last quarter. Capital World Investors boosted its holdings in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after purchasing an additional 23,146 shares in the last quarter. Capital International Investors boosted its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after acquiring an additional 213,038 shares during the period. Putnam Investments LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after acquiring an additional 24,329 shares during the period. Finally, Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $932,571,000. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.